MONTREAL, Dec. 10, 2025 /CNW/ - Novartis Canada is pleased to announce that Scemblix ® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding ...
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML). In a study involving patients with CML in high-income countries, approximately half the patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results